Currently, pharmacotherapy of coronary heart disease, based on antianginal drugs directly improve coronary blood flow, antiplatelet, and lipid-lowering drugs, includes a new class of drugs - cardiocytoprotectors. Recent ischemic cardiomyocytes improve security in the ATP, by optimizing the energy metabolism by reducing the need for oxygen cardiomyocytes and has an antioxidant effect, protecting cellular structures and enzymes from oxidative stress accompanying hypoxia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18565/cardio.2015.10.90-95 | DOI Listing |
Publication Analysis
Top Keywords
[cytoprotection cardiology
4
cardiology achievements
4
achievements prospects]
4
prospects] currently
4
currently pharmacotherapy
4
pharmacotherapy coronary
4
coronary heart
4
heart disease
4
disease based
4
based antianginal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!